¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"basal enzyme"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • proteolytic enzyme
    ´Ü¹éÁúºÐÇØÈ¿¼Ò
  • packaging enzyme
    ²Ù¸®±âÈ¿¼Ò, Æ÷ÀåÈ¿¼Ò
  • periplasmic enzyme
    ¿øÇüÁú¸·ÁÖÀ§È¿¼Ò
  • rate limiting enzyme
    ¼ÓµµÁ¦ÇÑÈ¿¼Ò
  • receptor destroying enzyme
    ¼ö¿ëüÆÄ±«È¿¼Ò
  • redox enzyme
    »êȭȯ¿øÈ¿¼Ò
  • reducing enzyme
    ȯ¿øÈ¿¼Ò
  • regulatory enzyme
    Á¶ÀýÈ¿¼Ò
  • respiratory enzyme
    È£ÈíÈ¿¼Ò
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
  • splitting enzyme
    ºÐ¸®È¿¼Ò
  • steatolytic enzyme
    Áö¹æºÐÇØÈ¿¼Ò
  • uricolytic enzyme
    ¿ä»êºÐÇØÈ¿¼Ò
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • packaging enzyme
    ²Ù¸®±âÈ¿¼Ò
  • periplasmic enzyme
    ¿øÇüÁú¸·ÁÖÀ§È¿¼Ò
  • phosphorylating enzyme
    ÀλêÈ­È¿¼Ò
  • proteolytic enzyme
    ´Ü¹éÁúºÐÇØÈ¿¼Ò
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò
  • receptor destroying enzyme
    ¼ö¿ëüÆÄ±«È¿¼Ò
  • redox enzyme
    »êȭȯ¿øÈ¿¼Ò
  • reducing enzyme
    ȯ¿øÈ¿¼Ò
  • regulatory enzyme
    Á¶ÀýÈ¿¼Ò
  • respiratory enzyme
    È£ÈíÈ¿¼Ò
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
  • splitting enzyme
    ºÐ¸®È¿¼Ò
  • steatolytic enzyme
    Áö¹æºÐÇØÈ¿¼Ò
  • uricolytic enzyme
    ¿ä»êºÐÇØÈ¿¼Ò
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • induced enzyme
    À¯µµÈ¿¼Ò.
  • inducible enzyme
    À¯¹ß°¡´ÉÈ¿¼Ò
  • inducible enzyme
    À¯µµ(¹ß)È¿¼Ò.
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inorganic enzyme
    ¹«±âÈ¿¼Ò(ÙíѦý£áÈ).
  • intracellular enzyme
    ¼¼Æ÷³»È¿¼Ò.
  • lipoclastic enzyme
    ÁöÁúºÐÇØÈ¿¼Ò.
  • lipolytic enzyme
    ÁöÁúºÐÇØÈ¿¼Ò.
  • lipolytic enzyme 192
    ÁöÁúºÐÇØÈ¿¼Ò 192
  • microsomal enzyme
    ¹Ì¼Òüȿ¼Ò.
  • milk clotting enzyme
    ÀÀÀ¯È¿¼Ò(ëêêáý£áÈ).
  • mst ii restriction enzyme
    Mst II Á¦ÇÑÈ¿¼Ò(¡­ ð¤ùÚý£áÈ)
  • mucolytic enzyme
    ¹Â½Å¾×ºÐÇØÈ¿¼Ò.
  • one gene one enzyme theory
    ÀÏÀ¯ÀüÀÚ- ÀÏÈ¿¼Ò(´ëÀÀ)¼³(ìéë¶îîí­ìéý£áÈÓßëëæò).
  • oxidation enzyme =oxidase
    »êÈ­È¿¼Ò(ß« ûùý£áÈ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • enzyme pH electrode
    È¿¼Ò(ý£áÈ) pH Àü±Ø(ï³Ð¿)
  • enzyme replacement therapy
    È¿¼Ò ´ëü Ä¡·á (ý£áÈÓÛôðö½Öû)
  • enzyme repression
    È¿¼Ò¾ïÁ¦(ý£áÈåäð¤)
  • enzyme species
    È¿¼ÒÁ¾(ý£áÈðú)
  • enzyme-specific electrode
    È¿¼ÒƯÀÌ Àü±Ø (ý£áÈ÷åì¶ï³Ð¿)
  • enzyme specificity
    È¿¼ÒƯÀ̼º(ý£áÈ÷åì¶àõ)
  • enzyme-substrate complex
    È¿¼Ò-±âÁú º¹ÇÕü (ý£áÈÐñòõÜÜùêô÷)
  • enzyme-substrate compound
    È¿¼Ò-±âÁú È­ÇÕ¹° (ý£áÈÐñòõûùùêÚª)
  • enzyme-substrate intermediate
    È¿¼Ò-±âÁú Áß°£Ã¼ (ý£áÈÐñòõñéÊàô÷)
  • enzyme system
    È¿¼Ò (ý£áÈ) ½Ã½ºÅÛ
  • enzyme therapy
    È¿¼ÒÄ¡·á (ý£áÈö½Öû)
  • enzyme unit
    È¿¼Ò´ÜÀ§ (ý£áÈÓ¤êÈ)
  • enzyme variant
    È¿¼Ò º¯ÀÌü(ý£áÈܨì¶ô÷)
  • essential enzyme
    Çʼö È¿¼Ò (ù±âÎý£áÈ)
  • extracellular enzyme
    ¼¼Æ÷¿Ü È¿¼Ò(á¬øàèâý£áÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
BME basal medium Eagle; biundulant meningoencephalitis; brief maximal effort
BMR basal metabolic rate
BOR basal optic root; before time of operation; bowels open regularly; branchio-oto-renal [syndrome]
BPO basal pepsin output; benzyl penicilloyl
BSR basal skin resistance; blood sedimentation rate; bowel sounds regular; brain stimulation reinforceme...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
ELISA Enzyme Linked Immuno Sorbant Assay
ACE ANG I converting enzyme
ACE ANGIOTENSIN CONVERTING ENZYME
ACEI Angiotensin Converting Enzyme Inhibitor
ACEi Angiotensin I converting enzyme inhibition
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • inferior basal vein
    ¾Æ·¡ ¹Ù´Ú Á¤¸Æ
  • lateral basal brach
    °¡ÂÊ ¹Ù´Ú °¡Áö
  • lateral basal segment
    °¡ÂÊ ¹Ù´Ú ±¸¿ª
  • morphealike basal cell carcinoma
    ¹Ý»ó °æÇÇÁõ °°Àº ±âÀú ¼¼Æ÷¾Ï
  • superior basal vein
    À§¹Ù´Ú Á¤¸Æ
  • undifferentiated basal cell carcinoma
    ¹ÌºÐÈ­ ±âÀú ¼¼Æ÷ ¾Ï
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
Eagle's basal medium A solution of various salts containing 13 naturally occurring amino acids, several vitamins, two antibiotics, and phenol red; used as a tissue culture medium.
(05 Mar 2000)
Engelmann's basal knobs An obsolete eponym for blepharoplast.
(05 Mar 2000)
junctional basal lamina <cell biology> Specialised region of the extracellular matrix surrounding a muscle cell, at the neuromuscular junction. May be responsible for localisation of acetylcholine receptors in the synaptic region and also binds acetylcholine esterase to this region
(18 Nov 1997)
lateral basal branch Lateral basal branch of the following: 1) basal part of inferior lobar branch of right pulmonary artery; 2) basal part of inferior lobar branch of left pulmonary artery.
Synonym: ramus basalis lateralis.
(05 Mar 2000)
lateral basal segment Lateral basal segment of inferior lobe of right and left lung; between anterior and posterior basal segments.
Synonym: segmentum basale laterale.
(05 Mar 2000)
acetyl-activating enzyme A ligase that catalyses the reaction of acetate and CoA and ATP to form AMP, pyrophosphate, and acetyl-CoA. A key step in the activation of acetate.
Synonym: acetate thiokinase, acetate-CoA ligase, acetyl-activating enzyme, acetyl-CoA synthetase.
(05 Mar 2000)
acyl-activating enzyme <enzyme> Fatty acid thiokinase (long-chain), a ligase forming acyl-CoA, AMP, and pyrophosphate from long-chain fatty acids, ATP, and coenzyme A. Activity is independent of phosphatidylcholine
Registry number: EC 6.2.1.3
Synonym: acyl-activating enzyme, dodecanoyl-CoA synthetase, fatty acid thiokinase (long chain), acid-coenzyme a ligase, fatty acid-CoA ligase, acyl-CoA synthetase, acyl-CoA ligase, coash ligase, ciprofibroyl-CoA synthetase, pristanoyl-CoA synthetase, palmityl CoA synthetase, palmitoyl CoA synthetase, palmitoyl CoA ligase, fatty acyl-CoA synthetase, very long chain fatty acid acyl-CoA synthetase, vlcfa acyl-CoA synthetase, nafenopin-CoA ligase, palmitoyl-CoA synthase, faa2 gene product, faa2p protein, vlacs enzyme
(26 Jun 1999)
adaptive enzyme Inducible enzyme, an enzyme that can be detected in a growing culture of a microorganism, after the addition of a particular substance (inducer) to the culture medium, but was not detectable prior to the addition and can act on the inducer. A prototype is the beta-galactosidase of Escherichia coli, synthesised upon the addition of various galactosides, whether or not these are good substrates.
Compare: constitutive enzyme.
Synonym: adaptive enzyme.
(05 Mar 2000)
allosteric enzyme <biochemistry, chemistry> A regulatory enzyme whose activity is modified by the noncovalent binding of a particular metabolite at a site (the allosteric site) other than the active site.
(09 Oct 1997)
amino acid activating enzyme <enzyme> Enzymes catalyzing the formation of a specific aminoacyl-tRNA from an amino acid and adenosine 5'-triphosphate with the concomitant formation of adenosine 5'-monophosphate and pyrophosphate.
Synonym: amino acid activating enzyme, aminoacyl-tRNA ligases.
(05 Mar 2000)
angiotensin-converting enzyme <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I.
Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases.
Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels).
Drugs that inhibit ACE are used to treat hypertension and congestive heart failure.
See: angiotensin-converting enzyme inhibitor
Acronym: ACE
(12 Aug 2000)
angiotensin-converting enzyme inhibitor <pharmacology> A class of drugs used in the treatment of hypertension and heart failure.
They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
(14 Aug 2000)
angiotensin-converting enzyme secretase <enzyme> Converts ace from a membrane-bound to a soluble form; not inhibited by thiol, serine or acid enzyme inhibitor but is inhibited by edta and 1,10-phenanthroline
Registry number: EC 3.4.99.-
Synonym: ace secretase
(26 Jun 1999)
Antibody Directed Enzyme Prodrug Therapy <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately.
The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects.
Acronym: ADEPT
(14 Nov 1997)
antitumour enzyme <enzyme> An enzyme that stimulates the degradation of a particular metabolite that cannot be synthesised by tumour cells, inhibits the synthesis of a metabolite needed by tumour cells, or inhibits tumour-specific DNA utilization; e.g., asparaginase.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á